ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1772

Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program

Eman Satti1, Nawal Hadwan1 and Samar Al Emadi1, 1Hamad medical corporation, DOHA, Qatar

Meeting: ACR Convergence 2020

Keywords: infliximab, pregnancy, TNF-blocking Antibody

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic Disease-Modifying agents (bDMARDs) including TNF inhibitors are increasingly used during pregnancy over the last few decades for a variety of autoimmune conditions. Nevertheless, limited data is available regarding their safety through pregnancy, particularly in the third trimester. Previous reports of discriminated BCG and severe neonatal neutropenia has made many practitioners defer live-attenuated vaccines from the routine schedule. The international guidelines still recommend holding most TNF inhibitors for several half-lives before delivery, due to the significant levels found in the neonates. Many mothers are advised to adjust the immunization schedule of their infants accordingly.

Recent accumulating data from IBD in pregnancy started to support the safety of infliximab use throughout pregnancy. Due to the paucity of data in this regard, we have planned this study.

Methods: We surveyed the electronic records of two registries from the IBD and Rheumatology clinics at the largest tertiary hospital in Qatar. We included all women who completed their pregnancies on biologics (minimum of 3 months of biologic use during pregnancy). Cases of abortion, IUFD, and neonatal death were excluded. We have analyzed the clinical data of infants who were 6 months of age or older. Data were recorded in a pre-specified datasheet. Then we ran a descriptive analysis using SPSS software.

Results: Since 2017, we identified 30 completed pregnancies on TNF blockers. Out of these, twenty-five infants were more than 6 months of age.

Mean maternal age at pregnancy was 29.5 years (22-42)
Underlying autoimmune diseases: IBD (13), RA (7), PSA(2), SPA (3). 
TNF inhibitors used: Infliximab(7), Adalimumab(5), Etanercept(2), and Certolizumab (10).
The mean duration of TNF inhibitor use during pregnancy was 6.8 months (5-9 months).
TNF inhibitors were taken throughout pregnancy in 15 cases: certolizumab (6), Infliximab (4), and adalimumab (2). 
In 2 pregnancies, Etanercept was taken for 7 months followed by Certolizumab until birth. 

Mean gestational age at birth was 36.8 weeks (34-41). 
Prematurity was recorded in 7 cases (34-37 weeks) and LBW in 1 case.
Two neonates required NICU admission for ARDS. 
Five cases of neonatal jaundice were identified. No congenital anomalies reported. 

Immunization Data:
Live attenuated vaccines: Thirteen infants (52%) received BCG vaccine at birth, 17(68%) received ROTA vaccine at 2 months, 16 (64%) received ROTA booster at 4 months and 12 (46%) infants received MMR at 1 year. 
No complications related to the vaccines were recorded. 

Infections during Infancy:
Mean number of infection encounters during infancy was 2 encounters (0-5).
Infections reported were: URTI, bronchiolitis and otitis media. One infant got COVID19 mild infection. 
Mean number of encounters that required antibiotics was 10 in 9 infants. 

Conclusion: We have identified high rate of infants who received live-attenuated vaccines per the national immunization program without complications. This observation was also associated with high rate of maternal TNF inhibitor use throughout pregnancy. No alarming concern about repeated infections reported in this study.


Disclosure: E. Satti, None; N. Hadwan, None; S. Al Emadi, None.

To cite this abstract in AMA style:

Satti E, Hadwan N, Al Emadi S. Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/vaccinations-of-infants-born-to-mothers-on-tnf-inhibitors-safe-administration-of-live-vaccines-given-per-the-national-immunization-program/. Accessed April 14, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vaccinations-of-infants-born-to-mothers-on-tnf-inhibitors-safe-administration-of-live-vaccines-given-per-the-national-immunization-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.